Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Single Dose Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.

NCT04808154 is registered in ClinicalTrials.gov with Sinew Pharma Inc. as lead sponsor.

NCT NCT04808154
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04808154 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Single Dose Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.
Lead sponsor
Sinew Pharma Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 22, 2021
Completion date
August 31, 2021
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nash - nonalcoholic steatohepatitis